August 21, 2014 12:25 PM ET

Biotechnology

Company Overview of Epizyme, Inc.

Company Overview

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemi...

400 Technology Square

4th Floor

Cambridge, MA 02139

United States

Founded in 2007

74 Employees

Phone:

617-229-5872

Fax:

617-349-0707

Key Executives for Epizyme, Inc.

Chief Executive Officer
Age: 59
Total Annual Compensation: $564.7K
President
Age: 44
Total Annual Compensation: $513.2K
Chief Scientific Officer and Executive Vice President
Age: 57
Total Annual Compensation: $487.5K
Chief Medical Officer
Age: 49
Total Annual Compensation: $463.5K
Compensation as of Fiscal Year 2013.

Epizyme, Inc. Key Developments

Epizyme, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of 2014

Epizyme, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaboration revenue of $9,494,000 against $14,839,000 a year ago. Loss from operations was $13,311,000 against $2,177,000 a year ago. Loss allocable to common stockholders was $13,386,000 or $0.40 per basic and diluted share against $2,319,000 or $0.25 per basic and diluted share a year ago. For the six months, the company reported collaboration revenue of $22,885,000 against $23,721,000 a year ago. Loss from operations was $20,223,000 against $9,654,000 a year ago. Loss allocable to common stockholders was $20,270,000 or $0.63 per basic and diluted share against $9,973,000 or $1.82 per basic and diluted share a year ago. The company provided cash flow guidance for the full year 2014. The company continues to expect full-year 2014 net cash used in operating activities to be approximately $50 million, including $34 million in accounts receivable recorded in 2013 but collected in 2014. Excluding these accounts receivable, adjusted net cash used in operating activities in 2014 is expected to be approximately $80 million. The company expects to end 2014 with more than $170 million in cash and cash equivalents, which is expected to fund the company until at least mid-2016, prior to including any potential future milestone payments.

Epizyme Announces Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology

Epizyme, Inc. reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas. These data were presented by Robert Copeland, Ph.D., Chief Scientific Officer, Epizyme, during an oral session on novel therapeutics in lymphoma at the American Society of Hematology (ASH) meeting on Lymphoma Biology, held August 10-13 in Colorado Springs, Colorado. Pre-clinical data have shown the utility of single-agent EZH2 inhibitors in both EZH2 mutant and EZH2 wild type germinal center (GC) NHL models. Data presented showed that in pre-clinical studies in GC NHL cell lines, combining EPZ-6438 with CHOP, a chemotherapy cocktail regimen that is a standard of care in NHL, resulted in strong synergy of lymphoma cell killing. When EPZ-6438 was combined with each individual component of the CHOP regimen, the synergy was great with prednisone, the corticosteroid component of CHOP. Prednisone greatly enhanced the potency of EPZ-6438 for killing EZH2 mutant-bearing lymphoma cell lines, and broadened the activity of EPZ-6438 to all GC NHL cell lines, regardless of EZH2 mutational status. Combining EPZ-6438 with dexamethasone, another corticosteroid, yielded similar synergistic results. Synergy was also observed in both EZH2 mutant and wild type cell lines when EPZ-6438 was combined with B-cell signaling pathway agents and BCL2 antagonists. The primary objective of the ongoing Phase 1 dose escalation study is to evaluate the safety and tolerability of EPZ-6438 and determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D); the secondary objectives are to determine pharmacokinetics (PK) and pharmacodynamics (PD) of EPZ-6438. The study to date consists of five dosing cohorts, with evaluation of doses of 100 mg to 1600 mg BID, orally administered in 28-day cycles without a drug holiday in patients with advanced solid tumors or with relapsed or refractory B-cell lymphoma. Three of five dosing cohorts (100, 200 and 400 mg) have been completed with 12 evaluable patients dosed, four of whom were NHL patients. Dose cohorts evaluating 800 mg and 1600 mg are ongoing. Early clinical observations from the three completed cohorts include: MTD has not been reached; there were no DLTs or AE-related treatment discontinuations. PK was dose-proportional across these three cohorts. PD evidence of target inhibition was observed in skin. Two NHL patients achieved objective responses: a partial response in a patient with relapsed transformed diffuse large B-cell lymphoma (DLBCL), and an ongoing partial response in a patient with primary refractory mediastinal B-cell lymphoma (PMBCL). Additionally, a patient with follicular lymphoma with EZH2 mutation had stable disease.

Epizyme, Inc. to Report Q2, 2014 Results on Aug 13, 2014

Epizyme, Inc. announced that they will report Q2, 2014 results on Aug 13, 2014

Similar Private Companies By Industry

Company Name Region
Enavail, LLC United States
Oneighty C Technologies Corporation United States
AuraSense Therapeutics, LLC United States
PCAS-Nanosyn LLC United States
BioAegis Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Epizyme, Inc., please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.